CLASS clarification: Reaffirms the medical importance of the analyses and results

BMJ

Volumn 327, Issue 7418, 2003, Pages E143-

  Geis, G Steven ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007768013     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmjusa.02090004     Document Type: Article

References (9)

1. Jüni P, Rutjes AWS, Dieppe PA Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287–1288
2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–1255
3. FDA-Approved Celebrex Approved Prescribing Information (June 7, 2002): http://www.fda.gov/cder/foi/label/1998/20998lbl.pdf.
4. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333–1337
5. Celecoxib NDA, 1998.
6. Silverstein FE, Graham DU, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–249
7. Silverstein F, Simon L, Faich G Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. In reply. JAMA 2001; 286: 2399–2400
8. FDA Talk Paper: http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01151.html.
9. Goldstein JL for the CLASS invesigators Gastrointestinal (GI) event rates in the CLASS study: six months vs longer-term follow-up analyses. Gastroenterology 2002; 122 (4) Suppl 1: A-469